A query from medical practice: The biological half-life of biophosphonates;Frage aus der praxis: Biologische halbwertszeit von bisphosphonaten

Deutsche Medizinische Wochenschrift

Volumn 133, Issue 51-52, 2008, Pages 2700-2701

  Bartl, R ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; ETIDRONIC ACID; IBANDRONIC ACID; RISEDRONIC ACID; ZOLEDRONIC ACID; BONE DENSITY CONSERVATION AGENT;

BLOOD PRESSURE; DRUG BLOOD LEVEL; DRUG HALF LIFE; HUMAN; LETTER; MEDICAL PRACTICE; OSTEOPOROSIS; PH; BONE; HALF LIFE TIME; METABOLISM; TISSUE DISTRIBUTION;

BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; HALF-LIFE; HUMANS; HYDROGEN-ION CONCENTRATION; OSTEOPOROSIS; TISSUE DISTRIBUTION;

EID: 58149214032     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0028-1105880     Document Type: Letter

References (11)

1. Bartl R. Auf dem Weg zu einer rationalen Therapiedauer mit Bisphosphonaten. Dtsch Med Wochenschr 2007; 132 (11): 545
2. Bartl R. Osteoporose - Prävention, Diagnostik, Therapie. 3. Aufl. Stuttgart: Thieme, 2008
3. Bartl R, Frisch B, von Tresckow E, Bartls C. Bisphosphonates in medical practice. Heidelberg: Springer, 2007
4. Black D, Bilezikian J, Ensrud K et al. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med 2005; 353: 555-565
5. Black D, Delmas P, Eastell R et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356: 1809-1822
6. Black D, Schwartz A, Ensrud K. Effects of continuing or stopping alendronate after 5 years of treatment. The fracture intervention trial long-term extension (FLEX): a randomized trial. JAMA 2006; 296: 2927-2938
7. Bone H, Hosking D, Devogelaer J-P et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004; 350: 1189-1199
8. Fleisch H. Bisphosphonates in Bone Disease. 4th Ed. San Diego: Academic Press, 2000
9. Lyles K et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007; 357: 1799-1809
10. Nancollas G, Tang R et al. Mineral binding affinities and zeta potentials of bisphosphonates. J Bone Miner Res 2002; 17 (S1): 5368
11. Russell R, Watts N, Ebentino F, Rogers M. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008; 19: 733-759